Natco Pharma Ltd
NSE:NATCOPHARM

Watchlist Manager
Natco Pharma Ltd Logo
Natco Pharma Ltd
NSE:NATCOPHARM
Watchlist
Price: 1 357.6 INR -1.25% Market Closed
Market Cap: 243.2B INR
Have any thoughts about
Natco Pharma Ltd?
Write Note

Natco Pharma Ltd
Accounts Receivables

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Natco Pharma Ltd
Accounts Receivables Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Accounts Receivables CAGR 3Y CAGR 5Y CAGR 10Y
Natco Pharma Ltd
NSE:NATCOPHARM
Accounts Receivables
â‚ą11.9B
CAGR 3-Years
42%
CAGR 5-Years
19%
CAGR 10-Years
26%
Dr Reddy's Laboratories Ltd
NSE:DRREDDY
Accounts Receivables
â‚ą80.3B
CAGR 3-Years
17%
CAGR 5-Years
15%
CAGR 10-Years
N/A
Cipla Ltd
NSE:CIPLA
Accounts Receivables
â‚ą55.9B
CAGR 3-Years
17%
CAGR 5-Years
7%
CAGR 10-Years
13%
Sun Pharmaceutical Industries Ltd
NSE:SUNPHARMA
Accounts Receivables
â‚ą129.4B
CAGR 3-Years
9%
CAGR 5-Years
9%
CAGR 10-Years
14%
T
Torrent Pharmaceuticals Ltd
NSE:TORNTPHARM
Accounts Receivables
â‚ą17.8B
CAGR 3-Years
5%
CAGR 5-Years
3%
CAGR 10-Years
4%
M
Mankind Pharma Ltd
NSE:MANKIND
Accounts Receivables
â‚ą8.5B
CAGR 3-Years
37%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Natco Pharma Ltd
Glance View

Market Cap
243B INR
Industry
Pharmaceuticals

NATCO Pharma Ltd. engages in the business of pharmaceuticals with research, manufacturing and marketing of finished dosage formulations and active pharmaceutical ingredients. The company is headquartered in Hyderabad, Telangana. The firm is engaged in the development, manufacture and commercialization of complex pharmaceuticals catering to niche therapeutic areas. The firm deals in the production of finished dosage formulations (FDF), which it sells in India, the United States and the Rest of the World, as well as active pharmaceutical ingredients (APIs). Its capabilities include multi-step synthesis, semi-synthetic fusion technologies, production of high-potency APIs and peptides. The firm operates through two segments: pharmaceuticals and agrochemicals. The pharmaceuticals segment, the Company drives its sales through FDFs and APIs. The agrochemicals segment is focused on niche products, including pest management.

NATCOPHARM Intrinsic Value
681.5 INR
Overvaluation 50%
Intrinsic Value
Price

See Also

What is Natco Pharma Ltd's Accounts Receivables?
Accounts Receivables
11.9B INR

Based on the financial report for Jun 30, 2024, Natco Pharma Ltd's Accounts Receivables amounts to 11.9B INR.

What is Natco Pharma Ltd's Accounts Receivables growth rate?
Accounts Receivables CAGR 10Y
26%

Over the last year, the Accounts Receivables growth was 39%. The average annual Accounts Receivables growth rates for Natco Pharma Ltd have been 42% over the past three years , 19% over the past five years , and 26% over the past ten years .

Back to Top